top of page

Tesamorelin

$110.00 Regular Price
$99.00Sale Price

Key Health Benefits:

  • Reduces abdominal fat
  • Enhances metabolic function
  • Supports muscle maintenance
  • Improves skin elasticity
  • Enhance mental clarity

Tesamorelin is a synthetic peptide designed to stimulate growth hormone (GH) release by mimicking growth hormone-releasing hormone (GHRH). Known for its effectiveness in reducing abdominal fat, Tesamorelin improves metabolic function, making it beneficial for those aiming to enhance body composition. It also supports muscle maintenance, which can improve strength and physical performance. Beyond body composition, Tesamorelin may provide anti-aging benefits, such as improved skin elasticity and potentially supporting cognitive health. Its combined effects on metabolism, fat reduction, and muscle preservation make Tesamorelin a valuable option for individuals seeking overall physical wellness and vitality.


RESEARCH REFERENCES ON TESAMORELIN

  1. Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV

Falutz J, Allas S, Blot K, et al. New England Journal of Medicine. 2007;357(23):2359-2370.

Randomized placebo-controlled trial showing tesamorelin reduced visceral adipose tissue over 26 weeks and improved lipid profiles in adults with HIV-associated central fat accumulation.

  1. Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients With Abdominal Fat Accumulation: A Randomized Clinical Trial

Stanley TL, Feldpausch MN, Oh J, et al. JAMA. 2014;312(4):380-389.

In a double-blind randomized trial, tesamorelin significantly reduced both visceral fat and liver fat over 6 months, supporting a potential benefit beyond abdominal adiposity alone.

  1. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial

Stanley TL, Fourman LT, Feldpausch MN, et al. The Lancet HIV. 2019;6(12):e821-e830.

Among people with HIV and NAFLD, tesamorelin lowered liver fat and reduced the likelihood of fibrosis progression, suggesting potential hepatic benefit in this population.

  1. Effects of Tesamorelin on Inflammatory Markers in HIV Patients with Excess Abdominal Fat: Relationship with Visceral Adipose Reduction

Stanley TL, Falutz J, Mamputu JC, et al. AIDS. 2011;25(10):1281-1288.

This randomized study reported favorable changes in selected inflammatory and fibrinolytic markers alongside visceral fat reduction, suggesting possible cardiometabolic benefit.

    bottom of page